Dr. Wenjie Liu, Amr A. K. Mousa, Austin M. Hopkins, Yin Fang Wu, Dr. Kelsie L. Thu, Dr. Michael Campbell, Dr. Simon J. Lees, Dr. Rithwik Ramachandran, Dr. Jinqiang Hou
{"title":"Front Cover: Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer (ChemMedChem 16/2024)","authors":"Dr. Wenjie Liu, Amr A. K. Mousa, Austin M. Hopkins, Yin Fang Wu, Dr. Kelsie L. Thu, Dr. Michael Campbell, Dr. Simon J. Lees, Dr. Rithwik Ramachandran, Dr. Jinqiang Hou","doi":"10.1002/cmdc.202481601","DOIUrl":null,"url":null,"abstract":"<p>The Front Cover shows a migrastatic candidate (LPA1 antagonist) that effectively suppresses triple-negative breast cancer (TNBC) migration and invasion, crucial processes leading to secondary tumors. Metastasis is responsible for about 90% of cancer mortality, while migrastatics, devoid of cytotoxicity, present a promising avenue to combat metastasis without inducing drug resistance. The findings offer hope for therapeutic interventions in the formidable realm of triple-negative breast cancer—a highly aggressive subtype. More details can be found in article 10.1002/cmdc.202400013 by Jinqiang Hou and co-workers. Cover design by Prof. Jinqiang Hou.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>\n </p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"19 16","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202481601","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202481601","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The Front Cover shows a migrastatic candidate (LPA1 antagonist) that effectively suppresses triple-negative breast cancer (TNBC) migration and invasion, crucial processes leading to secondary tumors. Metastasis is responsible for about 90% of cancer mortality, while migrastatics, devoid of cytotoxicity, present a promising avenue to combat metastasis without inducing drug resistance. The findings offer hope for therapeutic interventions in the formidable realm of triple-negative breast cancer—a highly aggressive subtype. More details can be found in article 10.1002/cmdc.202400013 by Jinqiang Hou and co-workers. Cover design by Prof. Jinqiang Hou.
期刊介绍：
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
